Decoding 9 Analyst Evaluations For Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Axsome Therapeutics, revealing an average target of $129.89, a high estimate of $190.00, and a low estimate of $95.00. Surpassing the previous average price target of $127.11, the current average has increased by 2.19%.
Interpreting Analyst Ratings: A Closer Look
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jason Gerberry | B of A Securities | Lowers | Neutral | $95.00 | $97.00 |
| Graig Suvannavejh | Mizuho | Maintains | Buy | $106.00 | $106.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $130.00 | $127.00 |
| Graig Suvannavejh | Mizuho | Lowers | Buy | $106.00 | $109.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| David Hoang | Citigroup | Lowers | Buy | $125.00 | $127.00 |
| Joel Beatty | Baird | Raises | Outperform | $112.00 | $108.00 |
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $115.00 | $90.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Axsome Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axsome Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
Discovering Axsome Therapeutics: A Closer Look
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
A Deep Dive into Axsome Therapeutics's Financials
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Axsome Therapeutics faced challenges, resulting in a decline of approximately -20.7% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Axsome Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -91.14%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -40.81%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -12.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 1.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.